GSK and Moderna settled patent litigation in the U.S. and Europe on October 28, 2026, granting mutual cross-licenses for infectious disease technologies without monetary payments. The agreement resolves legal disputes over lipid nanoparticle delivery systems in COVID-19 and RSV vaccines. Alongside the settlement, Moderna posted Q3 2026 net income of $162 million on $1.313 billion in revenue, driven by 29% growth and FDA approvals for its mFLUSIVA influenza vaccine.
GSK and Moderna patent settlement details
- ▪GSK and Moderna jointly filed a motion in a Delaware federal court on November 6, 2026 to dismiss GSK's U.S. patent infringement claims against Moderna with prejudice
- ▪Under the October 28, 2026 patent settlement, GSK and Moderna granted each other infectious disease patent cross-licenses with no monetary payments required by either company
- ▪GSK and Moderna settled all pending patent infringement lawsuits regarding Moderna's COVID-19 vaccines Spikevax and mNEXSPIKE and RSV vaccine mResvia
Moderna third-quarter 2026 financial results
- ▪Moderna raised its full-year 2026 revenue growth guidance to between 15% and 25%, up from its prior expectation of up to 10% growth
- ▪Moderna recorded third-quarter 2026 net income of $162 million, marking its first profitable quarter since its COVID-19 vaccine revenue peaked, compared to a net loss of $200 million in Q3 2025
- ▪Moderna reported third-quarter 2026 total revenue of $1.313 billion, representing a 29% increase from $1.016 billion in the third quarter of 2025
- ▪Moderna reported a net loss of $1.963 billion for the nine-month period ending September 30, 2026
FDA approvals for Moderna's influenza vaccine
- ▪The U.S. Food and Drug Administration granted accelerated approval for Moderna's mFLUSIVA for adults aged 65 and older, contingent on a confirmatory efficacy study
- ▪The U.S. Food and Drug Administration granted full approval for Moderna's influenza vaccine mFLUSIVA in August 2026 for adults aged 50 to 64
Story comments
Loading comments…